| Xing Liu,Xiaodong Xie. Research progression of PD-1/PD-L1 in non-small cell lung cancer. Oncol Transl Med, 2017, 3: 111-115. |
| Research progression of PD-1/PD-L1 in non-small cell lung cancer |
| Received:November 28, 2016 Revised:May 26, 2017 |
| View Full Text View/Add Comment Download reader |
| KeyWord:lung cancer; programmed cell death 1; programmed cell death-ligand 1; immunotherapy |
| Author Name | Affiliation | E-mail | | Xing Liu | Liaoning University of Traditional Chinese Medicine, Shenyang 110847, China | 13365864@qq.com | | Xiaodong Xie | Liaoning University of Traditional Chinese Medicine, Shenyang 110847, China | doctor_xxd@163.com |
|
| Hits: 7666 |
| Download times: 8812 |
| Abstract: |
| Lung cancer is the leading cause of cancer-related mortality worldwide. Despite great progress in the development of target agents, most people who do not harbor a mutation do not benefit from these agents. Immunotherapy, which stimulates the body’s immune system to improve the anti-tumor immunity effect, is a new therapeutic method for non-small cell lung cancer (NSCLC). Programmed cell death 1 (PD-1) and its ligand (PD-L1) belong to the CD28/B7 immunoglobulin super-family and are co-stimulatory molecules that show negative regulation effects. Combined with its ligand, PD-1 can modulate the tumor micro-environment, enabling tumor cells to escape host immune surveillance and elimination and play a key role in the clinical significance of NSCLC. An increasing number of clinical trials have suggested that immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 monoclonal antibodies, are beneficial and safe for NSCLC. Here, we review the brief history of PD-L1 as a biomarker, mechanism of action, and critical role of PD-1/PD-L1 in the treatment of NSCLC as well as the current research status and future directions. |
| Close |
|
|
|